William Blair launched coverage of Zura Bio (NASDAQ:ZURA) with an “outperform” rating and sum-of-the-parts NPV estimate of $13.90. The stock closed at $5.08 on July 7.
Zura is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet need. The company’s pipeline includes product candidates designed to target key mechanisms of immune system imbalance, with the goal of improving efficacy, safety, and dosing convenience for patients. Zura’s lead product candidate, tibulizumab (ZB-106), is currently being evaluated in two Phase 2 clinical studies in adults: TibuSHIELD, a study in hidradenitis suppurativa (HS), and TibuSURE, a study in systemic sclerosis (SSc). Zura plans to initiate a Phase 2 study for tibulizumab in a third immune-mediated indication by year end 2026. Additional product candidates, torudokimab (ZB-880) and crebankitug (ZB-168), have completed Phase 1/1b studies and are being evaluated for their potential across a range of autoimmune and inflammatory conditions.
“We believe there is significant translational data to support the role of both B cells and T cells in driving immunopathogenesis and inflammation in many autoimmune diseases, particularly HS and SSc,” writes analyst Matt Phipps, Ph.D. “By inhibiting both BAFF and IL-17, tibulizumab has the potential to benefit a broader range of patients with these diseases compared with single-target therapies, resulting in a greater percentage of patients responding to therapy and potentially deeper responses.”
“We estimate peak sales opportunity for tibulizumab of roughly $4 billion across these two indications [HS and SSc] alone, and clinical success in ongoing Phase II trials could result in expanded development over the longer term, offering upside to our current assumptions,” he adds.
